From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing pharmacological mechanisms and clinical features without systematic search methodology
PubMed 20600305 · doi:10.1016/j.pharmthera.2010.06.002
What was done
Narrative and comparative review evaluating the cellular, preclinical, and clinical profile of the antiparkinsonian drug piribedil. The review contrasts its receptor binding characteristics, specifically partial agonism at dopamine D2/D3 receptors and antagonism at alpha-2 adrenoceptors, with other dopamine agonists including pramipexole, ropinirole, and pergolide across motor dysfunction, depression, and cognitive impairment in Parkinson disease.
What was found
The abstract provides no quantitative data or specific numerical trial results. It qualitatively describes piribedil as having a profile of signal-specific partial agonism at dopamine D2 and D3 receptors, antagonistic action at alpha-2 adrenoceptors, and minimal activity at serotonergic receptors. The authors state this mechanism is sufficient to alleviate motor symptoms via supersensitive striatal D2 receptors while limiting adverse effects in normosensitive regions, and that alpha-2 antagonism reinforces adrenergic, dopaminergic, and cholinergic transmission.
Why it matters
Synthesizes the theoretical and clinical rationale for using partial dopamine agonists with alpha-2 adrenoceptor antagonist properties to target both motor and non-motor symptoms in Parkinson disease while attempting to reduce side effects associated with full dopamine agonists.
Limits
The abstract presents a narrative overview without systematic search criteria, quality appraisal, or quantitative data synthesis. No sample sizes, patient demographics, clinical trial designs, or statistical effect estimates are reported.
Cited by
- supports Piribedil increases levels of dopamine and norepinephrine.